Kristian W Pajtler

List of Publications by Year
in descending order

108	9,326	87888 38	48315 88
papers	citations	h-index	g-index

115	115	115	11411
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	SIOP Ependymoma I: Final results, long-term follow-up, and molecular analysis of the trial cohortâ€"A BIOMECA Consortium Study. Neuro-Oncology, 2022, 24, 936-948.	1.2	16
2	The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma. Cancers, 2022, 14, 679.	3.7	4
3	Controversies and challenges in the management of paediatric non-rhabdomyosarcoma soft tissue sarcomas. The Lancet Child and Adolescent Health, 2022, 6, 221-223.	5.6	10
4	SMARCB1-deficient and SMARCA4-deficient Malignant Brain Tumors With Complex Copy Number Alterations and TP53 Mutations May Represent the First Clinical Manifestation of Li-Fraumeni Syndrome. American Journal of Surgical Pathology, 2022, 46, 1277-1283.	3.7	3
5	The treatment approach to pediatric non-rhabdomyosarcoma soft tissue sarcomas: a critical review from the INternational Soft Tissue SaRcoma ConsorTium. European Journal of Cancer, 2022, 169, 10-19.	2.8	13
6	Genomic Evolution and Personalized Therapy of an Infantile Fibrosarcoma Harboring anNTRKOncogenic Fusion. JCO Precision Oncology, 2022, , .	3.0	4
7	EPEN-18. Oncogenic 3D genome conformations identify novel therapeutic targets in ependymoma. Neuro-Oncology, 2022, 24, i42-i42.	1.2	0
8	EPEN-19. Impact of molecular classification on prognosis in children and adolescents with spinal ependymoma: Results from the HIT-MED database. Neuro-Oncology, 2022, 24, i42-i43.	1.2	0
9	MODL-04. Drug screening in Disorders with Abnormal DNA Damage Response/Repair (DADDR) andin vivo validation. Neuro-Oncology, 2022, 24, i168-i169.	1.2	0
10	MEDB-60. Medulloblastoma with extensive nodularity mimics cerebellar development and differentiates along the granular precursor lineage. Neuro-Oncology, 2022, 24, i120-i120.	1.2	0
11	MEDB-38. Significance of CSF cytology and neurologic deterioration in relapsed medulloblastomas in the German HIT-REZ-97/-2005 Studies and the HIT-REZ-Register. Neuro-Oncology, 2022, 24, i113-i114.	1.2	0
12	MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. Neuro-Oncology, 2022, 24, i107-i107.	1.2	1
13	OTHR-32. The Pediatric Targeted Therapy 2.0 registry: robust molecular diagnostics for precision oncology. Neuro-Oncology, 2022, 24, i154-i154.	1.2	0
14	MODL-07. DNA methylation-based biobank of murine models for pediatric tumors. Neuro-Oncology, 2022, 24, i169-i170.	1.2	0
15	EPEN-28. Oncogenic dependency of pediatric ependymomas on extracellular vesicle pathways. Neuro-Oncology, 2022, 24, i45-i45.	1.2	0
16	HGG-61.Landscape of cancer predisposition in pediatric high-grade glioma. Neuro-Oncology, 2022, 24, i76-i76.	1.2	0
17	EPEN-09. Multi-omics characterization of the blood-brain barrier in molecular groups of ependymoma. Neuro-Oncology, 2022, 24, i40-i40.	1.2	0
18	PATH-11. Detection of genetic and epigenetic alterations in Liquid Biopsies from pediatric brain tumor patients. Neuro-Oncology, 2022, 24, i160-i161.	1.2	0

#	Article	IF	Citations
19	Evidence of neural crest cell origin of a DICER1 mutant CNS sarcoma in a child with DICER1 syndrome and NRASâ€mutant neurocutaneous melanosis. Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	4
20	Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a long-term follow-up. Neuro-Oncology, 2021, 23, 848-857.	1.2	24
21	The genetic landscape of choroid plexus tumors in children and adults. Neuro-Oncology, 2021, 23, 650-660.	1.2	26
22	Current recommendations for clinical surveillance and genetic testing in rhabdoid tumor predisposition: a report from the SIOPE Host Genome Working Group. Familial Cancer, 2021, 20, 305-316.	1.9	20
23	Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. Neuro-Oncology, 2021, 23, 1360-1370.	1.2	46
24	Predisposition to cancer in children and adolescents. The Lancet Child and Adolescent Health, 2021, 5, 142-154.	5.6	53
25	ZFTAâ€“RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma. Cancer Discovery, 2021, 11, 2200-2215.	9.4	46
26	ZFTA Translocations Constitute Ependymoma Chromatin Remodeling and Transcription Factors. Cancer Discovery, 2021, 11, 2216-2229.	9.4	32
27	Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusionâ€“Positive Supratentorial Ependymomas. Cancer Discovery, 2021, 11, 2230-2247.	9.4	39
28	Targeting fibroblast growth factor receptors to combat aggressive ependymoma. Acta Neuropathologica, 2021, 142, 339-360.	7.7	14
29	Cancer predisposition in pediatric neuro-oncologyâ€”practical approaches and ethical considerations. Neuro-Oncology Practice, 2021, 8, 526-538.	1.6	4
30	From Sampling to Sequencing: A Liquid Biopsy Pre-Analytic Workflow to Maximize Multi-Layer Genomic Information from a Single Tube. Cancers, 2021, 13, 3002.	3.7	15
31	Bioanalysis of selinexor in mouse plasma micro-samples utilizing UPLC-MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1176, 122781.	2.3	2
32	EPEN-03. ZFTA/C11ORF95 FUSIONS DRIVE SUPRATENTORIAL EPENDYMOMA VIA SHARED ONCOGENIC MECHANISMS. Neuro-Oncology, 2021, 23, i13-i14.	1.2	1
33	Development of Randomized Trials in Adults with Medulloblastomaâ€”The Example of EORTC 1634-BTG/NOA-23. Cancers, 2021, 13, 3451.	3.7	8
34	How we treat medulloblastoma in adults. ESMO Open, 2021, 6, 100173.	4.5	9
35	PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum. Acta Neuropathologica, 2021, 142, 841-857.	7.7	36
36	Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. Acta Neuropathologica, 2021, 142, 827-839.	7.7	33

#	Article	IF	Citations
37	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer Discovery, 2021, 11, 2764-2779.	9.4	110
38	Investigating the Central Nervous System Disposition of Actinomycin D: Implementation and Evaluation of Cerebral Microdialysis and Brain Tissue Measurements Supported by UPLC-MS/MS Quantification. Pharmaceutics, 2021, 13, 1498.	4.5	3
39	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	12.8	237
40	Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study. Neuro-Oncology, 2021, 23, 1012-1023.	1.2	19
41	Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies. Journal of Neuro-Oncology, 2021, 155, 193-202.	2.9	6
42	Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Cancer Cell, 2021, 39, 1519-1530.e4.	16.8	64
43	Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas. Acta Neuropathologica Communications, 2021, 9, 192.	5.2	5
44	Molecular characterization of histopathological ependymoma variants. Acta Neuropathologica, 2020, 139, 305-318.	7.7	43
45	YAP1-fusions in pediatric NF2-wildtype meningioma. Acta Neuropathologica, 2020, 139, 215-218.	7.7	45
46	Transcriptional profiling of medulloblastoma with extensive nodularity (MBEN) reveals two clinically relevant tumor subsets with VSNL1 as potent prognostic marker. Acta Neuropathologica, 2020, 139, 583-596.	7.7	13
47	Response to trametinib treatment in progressive pediatric low-grade glioma patients. Journal of Neuro-Oncology, 2020, 149, 499-510.	2.9	68
48	Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma. Cancer Cell, 2020, 38, 44-59.e9.	16.8	94
49	Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis. Genes and Development, 2020, 34, 1051-1064.	5.9	48
50	Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated ROS1/NTRK-Fusion Positive Pediatric High-Grade Glioma. Journal of Personalized Medicine, 2020, 10, 290.	2.5	18
51	cIMPACTâ€NOW update 7: advancing the molecular classification of ependymal tumors. Brain Pathology, 2020, 30, 863-866.	4.1	168
52	INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies. BMC Cancer, 2020, 20, 523.	2.6	24
53	Germline Elongator mutations in Sonic Hedgehog medulloblastoma. Nature, 2020, 580, 396-401.	27.8	94
54	The pediatric precision oncology study INFORM: Clinical outcome and benefit for molecular subgroups.. Journal of Clinical Oncology, 2020, 38, LBA10503-LBA10503.	1.6	12

#	Article	IF	Citations
55	EPEN-36. THE TREATMENT OUTCOME OF PAEDIATRIC SUPRATENTORIAL C11ORF95-RELA FUSED EPENDYMOMA: A COMBINED REPORT FROM E-HIT SERIES AND AUSTRALIAN NEW ZEALAND CHILDRENâ€™S HAEMATOLOGY/ONCOLOGY GROUP. Neuro-Oncology, 2020, 22, iii315-iii315.	1.2	0
56	EPEN-18. CROSS-SPECIES GENOMICS IDENTIFIES GLI2 AS AN ONCOGENE OF C11orf95 FUSION-POSITIVE SUPRATENTORIAL EPENDYMOMA. Neuro-Oncology, 2020, 22, iii311-iii311.	1.2	0
57	EPEN-44. EXTRACELLULAR VESICLES OF SUPRATENTORIAL EPENDYMOMA RELA MEDIATE INTERACTIONS WITH CELLS OF THE TUMOR MICROENVIRONMENT. Neuro-Oncology, 2020, 22, iii316-iii317.	1.2	0
58	EPEN-39. CLINICAL STRATIFIED TREATMENT OF LOCALIZED PEDIATRIC INTRACRANIAL EPENDYMOMA WITH COMBINED LOCAL IRRADIATION AND CHEMOTHERAPY WITHIN THE PROSPECTIVE, MULTICENTER E-HIT TRIAL â€“ THE MOLECULAR SUBGROUP MATTERS. Neuro-Oncology, 2020, 22, iii315-iii316.	1.2	1
59	MBRS-68. SINGLE NUCLEUS RNA-SEQUENCING DECIPHERS INTRATUMORAL HETEROGENEITY IN MEDULLOBLASTOMA WITH EXTENSIVE NODULARITY (MBEN). Neuro-Oncology, 2020, 22, iii410-iii410.	1.2	0
60	MYCN amplification drives an aggressive form of spinal ependymoma. Acta Neuropathologica, 2019, 138, 1075-1089.	7.7	104
61	YAP1 subgroup supratentorial ependymoma requires TEAD and nuclear factor I-mediated transcriptional programmes for tumorigenesis. Nature Communications, 2019, 10, 3914.	12.8	65
62	EPEN-04. CXorf67 MIMICS ONCOGENIC HISTONE H3 K27M MUTATIONS AND FUNCTIONS AS INTRINSIC INHIBITOR OF PRC2 FUNCTION IN AGGRESSIVE POSTERIOR FOSSA EPENDYMOMA. Neuro-Oncology, 2019, 21, ii78-ii78.	1.2	0
63	Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience. European Journal of Cancer, 2019, 114, 27-35.	2.8	51
64	EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma. Neuro-Oncology, 2019, 21, 878-889.	1.2	106
65	Evaluation of Storage Tubes for Combined Analysis of Circulating Nucleic Acids in Liquid Biopsies. International Journal of Molecular Sciences, 2019, 20, 704.	4.1	44
66	Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series. Oncologist, 2019, 24, e921-e929.	3.7	19
67	EANOâ€“EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. Lancet Oncology, The, 2019, 20, e715-e728.	10.7	56
68	Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging. Brain Pathology, 2019, 29, 325-335.	4.1	55
69	The landscape of genomic alterations across childhood cancers. Nature, 2018, 555, 321-327.	27.8	1,068
70	Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Nature, 2018, 553, 101-105.	27.8	170
71	Interrogating the enhancer landscape of intracranial ependymomas: perspectives for precision medicine. Expert Review of Precision Medicine and Drug Development, 2018, 3, 147-149.	0.7	1
72	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	27.8	1,872

#	Article	IF	Citations
73	Ependymoma. Seminars in Neurology, 2018, 38, 104-111.	1.4	45
74	Ependymoma. , 2018, , 177-192.		1
75	EPEN-07. OVEREXPRESSION AND MUTATIONS OF CXORF67 IN â€˜INFANT-TYPEâ€™ POSTERIOR FOSSA TYPE-A (PFA) EPENDYMOMAS. Neuro-Oncology, 2018, 20, i74-i74.	1.2	0
76	FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma. Acta Neuropathologica, 2018, 136, 293-302.	7.7	56
77	A Mouse Ependymoma Model Provides Molecular Insights into Tumor Formation. Cell Reports, 2018, 23, 3699-3700.	6.4	0
78	DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment. Neuro-Oncology, 2018, 20, 1616-1624.	1.2	65
79	Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica, 2018, 136, 227-237.	7.7	86
80	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncology, The, 2018, 19, 785-798.	10.7	268
81	Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Acta Neuropathologica, 2018, 136, 211-226.	7.7	199
82	Limitations of current in vitro models for testing the clinical potential of epigenetic inhibitors for treatment of pediatric ependymoma. Oncotarget, 2018, 9, 36530-36541.	1.8	7
83	Genetic confirmation that ependymoma can arise as part of multiple endocrine neoplasia type 1 (MEN1) syndrome. Acta Neuropathologica, 2017, 133, 661-663.	7.7	11
84	Childhood cancer predisposition syndromesâ€”A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. American Journal of Medical Genetics, Part A, 2017, 173, 1017-1037.	1.2	200
85	Recommendations for Cancer Surveillance in Individuals with RASopathies and Other Rare Genetic Conditions with Increased Cancer Risk. Clinical Cancer Research, 2017, 23, e83-e90.	7.0	122
86	Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clinical Cancer Research, 2017, 23, e38-e45.	7.0	358
87	Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain. Neuro-Oncology, 2017, 19, 1183-1194.	1.2	31
88	Molecular mechanisms and therapeutic targets in pediatric brain tumors. Science Signaling, 2017, 10, .	3.6	53
89	Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. Clinical Cancer Research, 2017, 23, e123-e132.	7.0	55
90	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathologica, 2017, 133, 5-12.	7.7	271

#	Article	IF	Citations
91	Epidemiology, molecular classification and WHO grading of ependymoma. Journal of Neurosurgical Sciences, 2017, 62, 46-50.	0.6	28
92	Clinical and molecular subgroups of ependymoma in adulthood: An analysis of the German Glioma Network.. Journal of Clinical Oncology, 2017, 35, 2038-2038.	1.6	1
93	The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models. Oncotarget, 2017, 8, 6730-6741.	1.8	34
94	Papillary Tumor of the Pineal Region: A Distinct Molecular Entity. Brain Pathology, 2016, 26, 199-205.	4.1	39
95	Telomere dysfunction and chromothripsis. International Journal of Cancer, 2016, 138, 2905-2914.	5.1	42
96	Toward an integrated histomolecular diagnosis of supratentorial ependymoma. Neuro-Oncology, 2016, 18, 893-894.	1.2	1
97	Intraventricular etoposide safety and toxicity profile in children and young adults with refractory or recurrent malignant brain tumors. Journal of Neuro-Oncology, 2016, 128, 463-471.	2.9	18
98	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal of Clinical Oncology, 2016, 34, 2468-2477.	1.6	160
99	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	28.9	702
100	Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma. Oncotarget, 2016, 7, 61860-61873.	1.8	27
101	<scp>M</scp>i<scp>R</scp>â€34a deficiency accelerates medulloblastoma formation in vivo. International Journal of Cancer, 2015, 136, 2293-2303.	5.1	40
102	Molecular dissection of ependymomas. Oncoscience, 2015, 2, 827-828.	2.2	19
103	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell, 2015, 27, 728-743.	16.8	933
104	Neuroblastoma in dialog with its stroma: NTRK1 is a regulator of cellular cross-talk with Schwann cells. Oncotarget, 2014, 5, 11180-11192.	1.8	26
105	The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma. Acta Neuropathologica Communications, 2013, 1, 19.	5.2	26
106	Expression of NTRK1/TrkA affects immunogenicity of neuroblastoma cells. International Journal of Cancer, 2013, 133, 908-919.	5.1	20
107	Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas. Neuro-Oncology, 2012, 14, 859-869.	1.2	48
108	Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation. Leukemia, 2012, 26, 2039-2051.	7.2	171